Addex Therapeutics Ltd. (ADXN) shareholders
Close on Nov 18, 2026Market cap $62.83KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Timothy Mark Dyer | 19,165,714 | 9.01% | 13D (active) amendment | Sep 2, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ADXN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| UBS Group AG | 47 | 0.00% | $268 | New | 0.00% |
| SBI Securities Co., Ltd. | 1 | 0.00% | $6 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2 | 0M | 0.0% | 1 / 0 | 0 / 3 | 0M | 0M |
| Q1 2026 | 4 | 0M | 0.0% | 0 / 1 | 0 / 1 | 0M | 0M |
| Q4 2025 | 5 | 0M | 0.0% | 1 / 1 | 2 / 0 | 0M | 0M |
| Q3 2025 | 4 | 0M | 0.0% | 1 / 0 | 0 / 2 | 0M | 0M |
| Q2 2025 | 5 | 0M | 0.0% | 1 / 0 | 1 / 1 | 0M | 0M |
| Q1 2025 | 5 | 0M | 0.0% | 0 / 1 | 3 / 0 | 0M | 0M |
| Q4 2024 | 5 | 0M | 0.0% | 3 / 2 | 0 / 1 | 0M | 0M |
| Q3 2024 | 3 | 0M | 0.0% | 1 / 1 | 1 / 0 | 0M | 0M |
| Q2 2024 | 2 | 0M | 0.0% | 1 / 1 | 0 / 0 | 0M | 0M |
| Q1 2024 | 1 | 0M | 0.0% | 1 / 0 | 0 / 3 | 0M | 0M |
| Q4 2023 | 3 | 0M | 0.1% | 3 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Timothy Mark Dyer | CHIEF EXECUTIVE OFFICER, Director | 435,192 | 0.29% | Nov 13, 2026 |
| Roger Mills | CHIEF MEDICAL OFFICER, Director | 785,976 | 0.53% | Nov 13, 2026 |
| Lenaic Nathanael Teyssedou | PRINCIPAL ACCOUNTING OFFICER | – | – | Nov 13, 2026 |
| Mikhail Kalinichev | HEAD OF TRANSLATIONAL SCIENCE | 0 | – | Sep 4, 2026 |
| Vincent Michael Lawton | Director | 2,507,987 | 1.70% | Nov 16, 2026 |
| Raymond George Hill | Director | 0 | – | Nov 16, 2026 |
| Jason Raleigh Nunn | Director | 219,561 | 0.15% | Nov 13, 2026 |
| Isaac Manke | Director | 219,561 | 0.15% | Nov 13, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jason Raleigh Nunn Director | Sep 2, 2026 | Award | +219,561 | – | – | 219,561 |
| Jason Raleigh Nunn Director | Sep 2, 2026 | Returned to company | −219,561 | – | – | 0 |
| Timothy Mark Dyer CHIEF EXECUTIVE OFFICER, Director | Sep 2, 2026 | Returned to company | −16,413,787 | – | – | 435,192 |
| Timothy Mark Dyer CHIEF EXECUTIVE OFFICER, Director | Sep 2, 2026 | Award | +16,413,787 | – | – | 16,848,979 |
| Mikhail Kalinichev HEAD OF TRANSLATIONAL SCIENCE | Sep 2, 2026 | Returned to company | −306,765 | – | – | 0 |
| Mikhail Kalinichev HEAD OF TRANSLATIONAL SCIENCE | Sep 2, 2026 | Award | +306,765 | – | – | 306,765 |
| Raymond George Hill Director | Sep 2, 2026 | Returned to company | −1,365,532 | – | – | 0 |
| Raymond George Hill Director | Sep 2, 2026 | Award | +1,365,532 | – | – | 1,365,532 |
| Roger Mills CHIEF MEDICAL OFFICER, Director | Sep 2, 2026 | Award | +392,837 | – | – | 785,976 |
| Roger Mills CHIEF MEDICAL OFFICER, Director | Sep 2, 2026 | Returned to company | −392,837 | – | – | 393,139 |
| Vincent Michael Lawton Director | Sep 2, 2026 | Award | +2,507,487 | – | – | 2,507,987 |
| Vincent Michael Lawton Director | Sep 2, 2026 | Returned to company | −2,507,487 | – | – | 500 |
| Isaac Manke Director | Sep 2, 2026 | Award | +219,561 | – | – | 219,561 |
| Isaac Manke Director | Sep 2, 2026 | Returned to company | −219,561 | – | – | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Addex Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 432,110 shares on Aug 24, 2026 over the last 90 days.
See a number that looks wrong?